Here are links for additional information and assistance in the treatment of Hodgkin's Lymphoma.

American Association for Cancer Research	www.aacr.org
American Cancer Society	www.cancer.org
American Society of Clinical Oncology	www.asco.org
American Society of Hematology	www.hematology.org
Leukemia & Lymphoma Society	www.leukemia.org
Lymphoma Research Society	www.lymphoma.org
National Cancer Institute	www.cancer.gov
National Comprehensive Care Network	www.nccn.org
National Organization for Rare Disorders (NORD)	www.rarediseases.org
Ulman Cancer Fund	www.ulmanfund.org

Important Safety Information

WARNING
It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.

Matulane is contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration. Due consideration of this possible state should be given to each patient who has leukopenia, thrombocytopenia, or anemia.

Matulane in combination therapy is a potent chemotherapeutic agent. Before prescribing Matulane, the sections in the Prescribing Information concerning usage in pregnancy, occurrence of secondary cancers, monitoring required in liver and kidney disease, hematologic effects, CNS effects, and potentiation associated with alcohol and MAO inhibitors should be carefully evaluated.

Please see full Prescribing Information for Matulane indications and usage, contraindications, and warnings including boxed WARNINGS, precautions, and adverse reactions.